The Trump administration has introduced a new Medicaid program, called the "GENEROUS" model, which it says will generate billions in prescription drug cost savings. However, critics argue the potential savings remain uncertain because the specifics of the negotiated deals have not been made public. Without transparency on how discounts or rebates are structured, independent analysts question whether the program will deliver on its financial promises. The lack of clear details leaves room for debate over whether this approach will truly benefit Medicaid recipients and taxpayers.
The Trump administration claims that Medicaid will save billions on prescription drug costs as a result of the plan, dubbed the Medicaid "GENEROUS" model. Experts say the savings are unclear since the content of the deals isn't public.
